ANI Pharmaceuticals, Inc.
ANIP
$70.10
-$0.14-0.19%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 978.38M | 923.71M | 883.37M | 826.88M | 747.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 978.38M | 923.71M | 883.37M | 826.88M | 747.40M |
| Cost of Revenue | 387.40M | 361.86M | 341.31M | 310.95M | 280.63M |
| Gross Profit | 590.98M | 561.85M | 542.06M | 515.94M | 466.77M |
| SG&A Expenses | 323.86M | 313.97M | 316.85M | 299.37M | 292.39M |
| Depreciation & Amortization | 85.80M | 89.45M | 91.42M | 91.40M | 84.52M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 846.98M | 816.97M | 801.24M | 757.77M | 711.42M |
| Operating Income | 131.40M | 106.73M | 82.13M | 69.11M | 35.98M |
| Income Before Tax | 142.60M | 116.03M | 95.79M | 50.55M | -14.75M |
| Income Tax Expenses | 34.29M | 23.88M | 17.45M | 9.98M | -4.54M |
| Earnings from Continuing Operations | 108.31 | 92.15 | 78.34 | 40.57 | -10.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 108.31M | 92.15M | 78.34M | 40.57M | -10.21M |
| EBIT | 131.40M | 106.73M | 82.13M | 69.11M | 35.98M |
| EBITDA | 217.21M | 196.18M | 173.55M | 160.51M | 120.50M |
| EPS Basic | 4.81 | 4.09 | 3.48 | 1.70 | -0.75 |
| Normalized Basic EPS | 3.42 | 2.72 | 1.98 | 1.49 | 0.46 |
| EPS Diluted | 4.63 | 3.94 | 3.35 | 1.63 | -0.77 |
| Normalized Diluted EPS | 3.29 | 2.62 | 1.90 | 1.45 | 0.45 |
| Average Basic Shares Outstanding | 82.83M | 81.51M | 80.20M | 78.96M | 78.29M |
| Average Diluted Shares Outstanding | 86.33M | 84.72M | 83.22M | 80.89M | 79.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.32% | 0.82% | 1.48% | 3.85% | -15.91% |